TP53 hotspot R282W in higher-risk MDS — dismal prognosis. Biallelic vs monoallelic per IP...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-R282W-MDS-HR |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MDS-HR |
| Sources | SRC-CIVIC SRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | R282W |
| Disease | DIS-MDS-HR |
| ESCAT tier | IIIB |
| Recommended combinations | azacitidine + venetoclax, alloSCT consideration, clinical trial |
| Evidence summary | TP53 hotspot R282W in higher-risk MDS — dismal prognosis. Biallelic vs monoallelic per IPSS-M scoring critical. |
Notes
ESCAT IIIB. R282W hotspot — score per IPSS-M biallelic algorithm.
Used By
No reverse references found in the YAML corpus.